

SPECTRX INC  
Form 8-K  
June 12, 2007

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): **June 11, 2007 (June 5, 2007)**

**SPECTRX, INC.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**  
(State or Other Jurisdiction of Incorporation)

**0-22179**  
(Commission File Number)

**58-2029543**  
(IRS Employer Identification No.)

**4955 Avalon Ridge Pkwy, Suite 300**  
**Norcross, Georgia**  
(Address of Principal Executive Offices)

**30071**  
(Zip Code)

Registrant's Telephone Number, Including Area Code: **(770) 242-8723**

---

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions :

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01. OTHER EVENTS  
SIGNATURES

---

**Table of Contents**

**Item 8.01            Other Events.**

On June 5, 2007, SpectRx, Inc. and Abbott Laboratories, Inc. entered into a settlement and release thereby settling pending legal disputes. As a result, SpectRx will drop its lawsuit and patent infringement claims against Abbott and Abbott will forgive approximately \$5.6 million in debt it claimed was in default. The disputes arose from a research, development and license agreement. The development agreement was terminated in January 2003. Under the settlement, neither party admitted any liability or wrongdoing.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SPECTRX, INC.**

/s/ MARK L. FAUPEL

By:

---

Mark L. Faupel, Ph.D.  
President & CEO

Date: June 11, 2007.